Results: On our database of 16,525 http://www.selleckchem.com/products/PF-2341066.html patients, 629 died, of which 120 (19%) (58 male) were 12 years or older (median 16.5 yrs (range 12-30 yrs)). A primary liver etiology was found in 62% with biliary atresia (17), malignant liver tumours (17), autoimmune liver disease (AILD) (11) and cystic fibrosis (11) as the most common conditions. 17 patients presented with fulminant liver failure requiring urgent listing and LT. Overall 52 patients (43%) underwent LT at a median age of 12.6 yrs (range 0.6-20 yrs), 18 (35%) required re-transplantation (re-LT) and 11 were re-listed (2 after re-LT) (table). Median
time between LT and re-LT was 10.7 yrs (0-20.8 yrs). For 27 LTs performed between 1984-95, the incidence of re-LT was 54% and re-listing for LT 19% compared to 16% and 24% respectively for 25 patients transplanted between 1996-2011. A further 9 patients were listed for primary LT and 2 were assessed but not activated (table). Median
survival following listing was 2.2 mths (range 0.1-17.3 mths). NA was documented in 16 patients (9 male) of which 14 LT patients (27%) and in the following conditions: biliary atresia selleck products (7/17), Wilson disease (4/7), autoimmune liver disease (2/11), FIC disease (2/3) and Crigler Najjar type 1 (1/2). NA was more prevalent in patients who underwent re-LT and who were re-listed (table). Fifty-six patients were recorded to have died in hospital. 77% were admitted to a paediatric or adult liver intensive care unit of which 16 were listed for LT. Eight patients, 2 listed for LT, died unexpectedly at home. Conclusion: NA appears to be an important
factor affecting graft and patient survival in young people with liver disease and is more common in patients who require re-LT or re-listing for LT. Median survival on the waiting list is short with 80% of listed patients Immune system dying in an intensive care setting. Disclosures: Nigel Heaton – Advisory Committees or Review Panels: Novartis, Roche; Speaking and Teaching: Astellas Michael A. Heneghan – Speaking and Teaching: Falk The following people have nothing to disclose: Marianne Samyn, Anil Dhawan Long-term Survival (LTS) prediction after Liver Transplant (LT) is important and significantly contributes to LT listing. The literature describes complications and poor outcome predictors but there is no established model to predict LTS > 20 yrs. Methods: Long-term (>20 years) and short-term survivors (< 1 and < 5 years) were compared. Univariate and multivariate logistic regressions were performed to identify variables associated with LTS. Stepwise multivariable models were built using these variables. Variables were organized in categories, each category was assigned a reference value to create a referent risk factor profile. A scoring system was created, 0 points were given to the base category, unhealthier risk factors were assigned positive points. Decision trees (DT) of LTS were created. Results: Of 3424 pts receiving a primary LT from 1984 to 2013, 211 survived > 20 yrs.